Comparing clinical outcomes in patients with type 2 diabetes mellitus after ischaemic stroke: Sodium–glucose cotransporter 2 inhibitors users versus non‐users. A propensity score matching National Cohort Study
Main finding · Recurrent ischaemic strokeResult — go to the resultHazard ratio 0.55 95% CI 0.34–0.88Authors' conclusion
Our findings indicate significantly lower risks of recurrent IS and all-cause mortality among patients with T2DM receiving SGLT2i treatment. Further studies are required to validate these results and investigate the underlying mechanisms behind the observed effects.
Study context
- Population
- Patients with T2D after ischaemic stroke, Taiwan's National Health Insurance Research Database, 1 May 2016 to 31 December 2019matched cohort
- Participants
- 707 vs 2,813
- Exposure
- SGLT2i users vs non-users after ischaemic stroke
- SGLT2in = 707
- Non-SGLT2in = 2,813reference
- Outcome
- Recurrent ischaemic stroke
Methodological detailsnationwide, propensity score matching, Follow-up from index date (3 months after index ischaemic stroke (IS)) until outcome, 6 months after index drug discontinuation, or 31 December 2020
- Nationwide
- Propensity score matching
- Follow-up from index date (3 months after index IS) until outcome, 6 months after index drug discontinuation, or 31 December 2020
Main finding
As reported in the abstract
Hazard ratio
0.55
95% CI 0.34–0.88
P = 0.0131
By group
SGLT2i
3.605% per year
Non-SGLT2i
5.897% per year
SGLT2ivs Non-SGLT2i
HR 0.55 (95% CI 0.34–0.88); P = 0.0131
Observational data: associations, not effects.
Further findings
Per year
| Outcome | SGLT2i | Non-SGLT2i | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| All-cause mortalityAfter propensity score matching | 5.396% | 7.489% | 0.58 (0.39–0.85) | P = 0.0058 | |
| 0.20.5125Hazard ratio (log scale) |
Acute MI, CV death, HF hospitalisation, lower limb amputation
- No significant differences in rates of acute MI, CV death, HF hospitalisation or lower limb amputation
Original publication
Comparing clinical outcomes in patients with type 2 diabetes mellitus after ischaemic stroke: Sodium–glucose cotransporter 2 inhibitors users versus non‐users. A propensity score matching National Cohort Study. Diabetes Obes Metab. Published 12 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →